Alliance Global Partners downgraded Alimera Sciences (ALIM) to Neutral from Buy after the company agreed to be bought by ANI Pharmaceuticals (ANIP) for $381M, or $5.50 per share, in cash upfront plus a CVR.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALIM:
- Alimera Sciences Set for Merger with ANI Pharmaceuticals
- ANI Pharmaceuticals sees ‘substantial accretion’ from Alimera Sciences deal
- ANI Pharmaceuticals to acquire Alimera Sciences for $381M upfront
- Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Alimera Sciences reports Q1 EPS (12c), consensus (6c)
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue